Home » Stocks » BAX

Baxter International, Inc. (BAX)

Stock Price: $86.96 USD 0.34 (0.39%)
Updated May 10, 2021 2:56 PM EDT - Market open
Market Cap 43.56B
Revenue (ttm) 11.82B
Net Income (ttm) 1.07B
Shares Out 505.00M
EPS (ttm) 2.07
PE Ratio 42.01
Forward PE 25.58
Dividend $0.98
Dividend Yield 1.13%
Trading Day May 10
Last Price $86.96
Previous Close $86.62
Change ($) 0.34
Change (%) 0.39%
Day's Open 87.18
Day's Range 86.82 - 87.57
Day's Volume 2,140,162
52-Week Range 74.32 - 90.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021. ...

5 days ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced an increase in the company's quarterly cash dividend to a rate of $0.28...

6 days ago - Business Wire

Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.

1 week ago - Zacks Investment Research

Baxter (BAX) delivered earnings and revenue surprises of 18.75% and 1.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2021. “Baxter's medically essential pro...

1 week ago - Business Wire

Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 weeks ago - Zacks Investment Research

Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.

2 weeks ago - Zacks Investment Research

Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced today that it has been recognized by the Global Inclusion Index in 11 countri...

2 weeks ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced it received a new research and development (R&D) grant from the German Federal Mini...

2 weeks ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May...

1 month ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that, due to the public health and safety concerns related to the novel...

1 month ago - Business Wire

DEERFIELD, Ill. & WASHINGTON--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, and the Central Area of The Links, Incorporated, an international not-for-...

1 month ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its first-quarter 2021 financial results on Thur...

1 month ago - Business Wire

Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.

1 month ago - Zacks Investment Research

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artific...

1 month ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 1...

1 month ago - Business Wire

Baxter International Inc (NYSE: BAX) has agreed to provide manufacturing services for Moderna Inc's (NASDAQ: MRNA) COVID-19 Vaccine. The agreement includes fill/finish sterile manufacturing services and...

Other stocks mentioned: MRNA
2 months ago - Benzinga

DEERFIELD, Ill., AND CAMBRIDGE, Mass..--(BUSINESS WIRE)--Baxter BioPharma Solutions and Moderna announce agreement for fill/finish manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Other stocks mentioned: MRNA
2 months ago - Business Wire

Baxter (BAX) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Generation Investment Management, the firm co-founded by Al Gore (Trades, Portfolio) and David Blood, disclosed this month that its top four buys during the fourth quarter of 2020 included a new positio...

Other stocks mentioned: BABA, EFX, ILMN
2 months ago - GuruFocus

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia Sc...

2 months ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $...

2 months ago - Business Wire

Baxter's (BAX) fourth-quarter results reflect robust performance across five of its business units.

3 months ago - Zacks Investment Research

Baxter (BAX) delivered earnings and revenue surprises of 5.26% and 0.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Baxter International (NYSE:BAX) moved higher by 0.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 1700.00% over the past year to $0.80...

3 months ago - Benzinga

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the fourth quarter and full year ended December 31, 2020, an...

3 months ago - Business Wire

Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.

3 months ago - Zacks Investment Research

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, ...

3 months ago - Business Wire

The pandemic is only a temporary setback for this diversified global manufacturer of medical devices.

Other stocks mentioned: BSX, MDT, SYK, TMO, XLV
3 months ago - The Motley Fool

According to the GuruFocus All-in-One Screener as of Jan. 15, the following Health Care stocks are popular among gurus.

Other stocks mentioned: A, CNC, VEEV, WBA
3 months ago - GuruFocus

We think that Baxter International currently is a better pick compared to Boston Scientific. BAX stock trades at about 3.6x trailing Revenues, compared to around 5.2x for Boston Scientific.

Other stocks mentioned: BSX
3 months ago - Forbes

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter BioPharma Solutions announced an agreement with Novavax to provide sterile manufacturing services for its COVID-19 vaccine candidate.

Other stocks mentioned: NVAX
3 months ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial results on Thu...

4 months ago - Business Wire

We believe that Baxter stock, a healthcare supply company, is a good buying opportunity at the present time. BAX stock trades near $80 currently and it is, in fact, down 16% from its pre-Covid high of $...

4 months ago - Forbes

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast. José (Jo...

4 months ago - Business Wire

Baxter's (BAX) Vital Edge program enables AdventHealth Tampa to achieve cost savings.

5 months ago - Zacks Investment Research

TAMPA, Fla.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, and AdventHealth Tampa today announced that AdventHealth Tampa will realize approxim...

5 months ago - Business Wire

The MS Global Franchise Fund (Trades, Portfolio), which is part of investment bank Morgan Stanley (NYSE:MS), disclosed its third-quarter portfolio earlier this week.

Other stocks mentioned: ADP, ICE, RBGLY
5 months ago - GuruFocus

Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.

5 months ago - Zacks Investment Research

Baxter's (BAX) Homechoice Claria combines a simple user interface with the benefits of Sharesource.

5 months ago - Zacks Investment Research

BAX offers a broad portfolio of essential, life-saving healthcare products to treat acute and chronic illnesses. There is no other competitor in the space that competes with BAX in all of their businesses.

5 months ago - Seeking Alpha

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of the Homechoice Claria autom...

5 months ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 3rd Annual HealthCONx virtual conference via webcast o...

5 months ago - Business Wire

Daniel Loeb (Trades, Portfolio) has revealed his portfolio for the third quarter. During the quarter, the guru added 20 new holdings, including PG&E Corp. (NYSE:PCG) and Microsoft Corp. (NASDAQ:MSFT).

Other stocks mentioned: FPAC, MSFT, PCG, RTX
5 months ago - GuruFocus

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $...

5 months ago - Business Wire

Daniel Loeb (Trades, Portfolio)'s Third Point Management sold shares of the following stocks during the third quarter, which ended on Sept. 30.

Other stocks mentioned: RTX
5 months ago - GuruFocus

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today published its first Sustainability Accounting Standards Board (SASB) index, a vol...

5 months ago - Business Wire

LONDON--(BUSINESS WIRE)-- #GlobalIntravenousFluidBagsMarket--The Intravenous Fluid Bags Market will grow by $ 667.51 mn during 2020-2024

Other stocks mentioned: AMCR
5 months ago - Business Wire

About BAX

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical... [Read more...]

Industry
Medical Instruments & Supplies
Founded
1931
CEO
Jose Almeida
Employees
50,000
Stock Exchange
NYSE
Ticker Symbol
BAX
Full Company Profile

Financial Performance

In 2020, BAX's revenue was $11.67 billion, an increase of 2.74% compared to the previous year's $11.36 billion. Earnings were $1.10 billion, an increase of 10.09%.

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for BAX stock is "Buy." The 12-month stock price forecast is 93.50, which is an increase of 7.53% from the latest price.

Price Target
$93.50
(7.53% upside)
Analyst Consensus: Buy